RxDoctor Payments Data

Peter Santucci, MD

Cardiovascular Disease · Maywood, ILNPI 1295804789

Payments from drug & device makers

$30,077in general payments, 2019–2025

Across 144 payments — averaging $208.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Microport CRM USA Inc$12K
  • Cardiofocus, Inc.$7K
  • Abbott$6K
  • Boston Scientific$2K
  • Biosense Webster, Inc.$1K
  • Medtronic$905
  • plus $2K from 8 others

What the payments were for

  • Consulting fees$3,52920%
  • Travel & lodging$8,57548%
  • Food & beverage$5,72932%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Microport CRM USA Inc2$12,245
Cardiofocus, Inc.2$6,778
Abbott33$5,674
Boston Scientific49$1,711
Biosense Webster, Inc.28$1,198
Medtronic(2 entities)5$905
Biotronik Inc.17$870
Volta Medical Inc2$458
Tempus AI, Inc1$122
Novartis1$28
Atricure, Inc.1$27
Cardiva Medical, Inc.1$24
Johnson & Johnson1$19
Cordis US CORP.1$17

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$30,077 in reported general payments places this provider in the 85th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$257,034
Medicare patients
931
Services billed
3,052

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban311$377,568
MultaqDronedarone Hcl112$212,041
XareltoRivaroxaban98$114,765
Dofetilide97$43,894
Flecainide Acetate135$5,220
Metoprolol Succinate170$3,367
Amiodarone Hcl110$1,505
SotalolSotalol Hcl46$1,066
Diltiazem 24hr Er (Cd)Diltiazem Hcl32$891
Diltiazem 24hr Er (Xr)Diltiazem Hcl11$638
Dilt-XrDiltiazem Hcl11$479
Metoprolol Tartrate32$178

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$19$114,76598 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Maywood

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →